Key Points
- CorVel VP Jennifer Yoss sold 1,999 shares on May 26 at an average price of $61.02, totaling about $121,979. After the sale, she held 2,173 shares, a 47.91% reduction in her stake.
- CRVL shares were down 2.7% and opened at $59.40, near its 50-day moving average of $56.43 and below its 200-day moving average of $61.35. The stock has traded between $44.83 and $113.64 over the past year.
- CorVel reported solid quarterly results with earnings of $0.61 per share and revenue of $248.55 million, while maintaining a 11.51% net margin and 29.92% return on equity. However, analyst sentiment remains cautious, with Weiss Ratings downgrading the stock to a "sell" and MarketBeat showing an average sell rating.
CorVel Corp. (NASDAQ:CRVL - Get Free Report) VP Jennifer Yoss sold 1,999 shares of the company's stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $61.02, for a total transaction of $121,978.98. Following the transaction, the vice president owned 2,173 shares in the company, valued at $132,596.46. The trade was a 47.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
CorVel Trading Down 2.7%
Shares of CRVL opened at $59.40 on Thursday. The firm's 50-day moving average is $56.43 and its two-hundred day moving average is $61.35. CorVel Corp. has a twelve month low of $44.83 and a twelve month high of $113.64. The firm has a market capitalization of $3.01 billion, a P/E ratio of 27.76 and a beta of 0.98.
CorVel (NASDAQ:CRVL - Get Free Report) last issued its earnings results on Tuesday, May 19th. The business services provider reported $0.61 earnings per share for the quarter. CorVel had a net margin of 11.51% and a return on equity of 29.92%. The company had revenue of $248.55 million for the quarter.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings lowered shares of CorVel from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Monday, April 6th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Sell".
Read Our Latest Analysis on CRVL
Institutional Trading of CorVel
Large investors have recently modified their holdings of the business. Principal Financial Group Inc. grew its position in shares of CorVel by 15.6% in the third quarter. Principal Financial Group Inc. now owns 162,111 shares of the business services provider's stock valued at $12,551,000 after purchasing an additional 21,827 shares during the last quarter. Argent Capital Management LLC acquired a new stake in shares of CorVel in the fourth quarter valued at approximately $1,800,000. Thrivent Financial for Lutherans grew its position in shares of CorVel by 14.6% in the third quarter. Thrivent Financial for Lutherans now owns 458,326 shares of the business services provider's stock valued at $35,484,000 after purchasing an additional 58,323 shares during the last quarter. Y Intercept Hong Kong Ltd grew its position in shares of CorVel by 665.2% in the third quarter. Y Intercept Hong Kong Ltd now owns 26,383 shares of the business services provider's stock valued at $2,043,000 after purchasing an additional 22,935 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in shares of CorVel by 1.4% in the third quarter. Vanguard Group Inc. now owns 3,287,788 shares of the business services provider's stock valued at $254,541,000 after purchasing an additional 45,071 shares during the last quarter. 51.36% of the stock is currently owned by institutional investors and hedge funds.
CorVel Company Profile
(
Get Free Report)
CorVel Corporation (NASDAQ: CRVL) is a technology-driven provider of workers' compensation, liability, and specialty risk management solutions. The company develops and deploys software and data analytics tools to streamline claims administration, medical cost containment, prescription drug management, and provider network access. CorVel's integrated platform connects employers, insurers, healthcare providers, and injured workers, aiming to improve outcomes and control costs through process automation and real-time decision support.
The company's product suite includes claims lifecycle management, bill review and negotiation, virtual care and telehealth services, pharmacy benefit management, and independent medical examinations (IMEs).
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
